Author: garysagiv0045

  • What’s new this week in MedTech, 23 to 30 October 2026

    What’s new this week in MedTech, 23 to 30 October 2026

    23 to 30 October 2026

    World Stroke Day on 29 October set the tone for a week in which remote robotics, AI imaging and new regulatory designations all pushed further into stroke and neurocritical care, while Brussels kept working on the MDR reform and investors put fresh money into brain implants, wearables and virtual testing.

    1. XCath shows the first remote robotic stroke thrombectomy to the world on World Stroke Day On 29 October XCath released a documentary on Operation Robo Angel, in which a neurointerventional surgeon at a control station in Santiago, Panama used the company’s Iris robot to remove a clot from a stroke patient in Panama City on the first pass, a procedure first performed in March and followed by FDA Breakthrough Device designation and entry into the FDA TAP pilot. It matters because most thrombectomy capable hospitals are concentrated in a handful of countries, and remote intervention could bring that care to patients who today have no specialist nearby, although the Iris system is still in development and not cleared for sale. Source: Medical Device Developments and NeuroNews International

    2. FDA gives Breakthrough status to a system that filters blood from spinal fluid after brain bleeds Pharaoh Neuro announced on 28 October that its Neurapheresis CSF Management System, a closed loop external platform that removes blood and its breakdown products from the cerebrospinal fluid of patients after aneurysmal subarachnoid hemorrhage, received FDA Breakthrough Device designation and is also taking part in the TAP pilot. It matters because there is currently no cleared or approved device that actively clears blood from the CSF in this young patient group, and the combination of designation and TAP gives the company a faster, more interactive route with the agency. Source: PR Newswire (Pharaoh Neuro)

    3. Brainomix AI on simple CT scans points to which severe stroke patients may benefit from a new drug In a post hoc analysis of the Phase 3 CHARM trial announced on 28 October, Brainomix used automated non contrast CT analysis in 428 patients and found that the investigational drug CIRARA was significantly associated with better outcomes in the subgroup with an infarct core below 125 mL. It matters because selecting patients with the most widely available stroke scan, rather than advanced imaging, could open trials and future treatments to far more hospitals, although the findings are exploratory and the drug is not approved. Source: PR Newswire (Brainomix)

    4. Empatica launches an FDA cleared and CE marked Parkinson’s wearable for home use Reported on 29 October, WellPD pairs a wrist worn device with an app that turns movement and other signals into daily measures of activity, sleep, tremor, bradykinesia and dyskinesia, lets patients log medication against those changes, and is now available to order in the US and several European countries. It matters because it is a clear example of neurology monitoring moving out of the clinic and into the home, giving clinicians data on what happens between appointments. Source: Medical Device Network

    5. EU Council working party takes up a third compromise on the MDR and IVDR reform On 26 and 27 October the Council’s Working Party on Pharmaceuticals and Medical Devices met in Brussels to exchange views on the Presidency’s third compromise text of the regulation simplifying the medical device rules, with expert panels and the link to the AI Act on the table. It matters because the proposal would replace the five year certificate cycle with risk based reviews, move much medical software from Class IIa to Class I and cut notified body fees for micro and small manufacturers, but it is still a proposal and today’s MDR and IVDR rules apply until a final text is adopted. Source: Council of the EU meeting notice and The European Post

    6. adsilico raises £10M to test devices in AI generated virtual patients The University of Leeds spinout announced on 27 October a Series A led by PXN Ventures to expand its technology, which builds virtual hearts and vessels from anonymised scans and simulates device performance across populations, and to extend it to brain devices such as flow diverters for aneurysms. It matters because in silico evidence could help manufacturers answer questions about diverse patient groups earlier and more cheaply, particularly in neurovascular areas where trials are small. Source: Intelligent Health.tech

    7. StimCardio closes a $30M Series A for a wrist worn atrial fibrillation therapy Announced on 29 October and led by Metis MedTech, the round funds the NeuroPulse 2 pivotal study of Rhyvive, an investigational wearable that delivers non invasive median nerve stimulation to reduce AF recurrence after catheter ablation, and preparation for an FDA De Novo submission. It matters because it shows investors backing non invasive neuromodulation as a therapy category in its own right, a trend that is equally relevant to neurology and rehabilitation devices. Source: PR Newswire (StimCardio)

    8. NeuroXess raises RMB 700M for a fully implanted wireless brain implant The Chinese brain-computer interface company reported on 28 October a Series B co-led by SDIC Juli, Shenzhen Capital Group and Qinzhi Capital, saying it has completed 65 clinical cases and began a registration trial with nearly 20 hospitals in July. It matters because China’s implant developers are moving quickly from clinical cases toward registration and large scale manufacturing, adding real competition to the US led brain-computer interface field. Source: TechNode and 36Kr

    Gary’s take What stands out for me this week is how much of the progress in stroke and neurocritical care is now coming through regulatory tools like Breakthrough designation and the TAP pilot, which give small companies a real seat at the table with FDA long before they file, and I would encourage any neuro startup with a serious unmet need to look at that route early. At the same time the EU reform is getting closer but is not there yet, so my advice remains to plan your CE strategy on today’s MDR and treat the proposed relief for software and small manufacturers as an upside rather than a planning date.

    Which of these developments matters most for your company, and is there an area you would like me to cover in more depth next week? You are always welcome to write to me directly.


    Sources note: all items were found through a public web scan of the week and each was checked against the linked original source.

    Website: synergenmedtech.com | LinkedIn: linkedin.com/company/100981535 | YouTube: youtube.com/@synergenmedtech

  • What’s new this week in MedTech, 17 to 24 October 2026

    What’s new this week in MedTech, 17 to 24 October 2026

    17 to 24 October 2026

    This week brought long term certainty for CE marked devices in Britain, a new global standard for stroke rehabilitation, a cleared AI tool for early Alzheimer’s risk, and more signs that regulators and investors are building the rules and the money around brain technology and software.

    1. UK confirms it will keep recognizing CE marked medical devices On 21 October the MHRA confirmed that Great Britain will continue to accept CE marked medical devices and IVDs on a long term basis, so manufacturers already approved for the EU market will not need an additional approval route, while the UKCA route stays alongside it and is being modernised. It matters because it removes a duplication risk that many companies had been planning around, and it gives export strategies for the British market a stable footing. Source: GOV.UK (MHRA)

    2. World Stroke Organization launches a stroke rehabilitation certification program The program, with 55 evidence based criteria and three certification tiers, was scheduled to be launched at the World Stroke Congress in Seoul on 23 October, after a pilot in 15 centers across six countries. It matters because rehabilitation has lagged behind acute stroke care, and a shared standard gives rehab services, and the technology companies that supply them, a common bar to build and prove value against. Source: Curtin University and World Stroke Congress 2026 programme

    3. FDA clears an AI tool that reads brain MRI to help judge Alzheimer’s risk NeuroXT announced on 20 October that its NEXT-Cue software received FDA 510(k) clearance, combining brain MRI, demographics and cognitive test results to help clinicians assess whether a patient with mild cognitive impairment may progress to Alzheimer’s dementia within five years. It matters because prognostic AI is now moving from research papers into cleared clinical software, which raises the evidence bar for every neurology software company that follows. Source: PR Newswire (NeuroXT)

    4. Paradromics and Siemens Healthineers plan a standard imaging workflow for brain implants Announced on 19 October, the collaboration aims to build an end to end imaging package covering candidate selection, surgical planning, navigation and follow up for implantable brain-computer interfaces, starting with speech and motor function. It matters because repeatable implantation workflows are a precondition for taking these devices beyond a few research centers, although this is still a plan and not a product. Source: Paradromics

    5. Coherence Neuro raises $45M for an implant that monitors brain tumors The Series A, co-led by Founders Fund and the OpenAI Startup Fund and reported on 23 October, will fund a first long term human trial in glioblastoma, and the devices remain investigational and not approved by the FDA. It matters because investors keep backing brain-computer interface platforms that reach well beyond paralysis into oncology and other fields. Source: MobiHealthNews

    6. A rehab robot that learns from physical therapists MIT Technology Review reported on 20 October on a Purdue and MIT system that uses generative AI and real-time force feedback to give stroke patients just the right amount of help during reaching and lifting exercises. It matters because therapist shortages limit stroke recovery, and the researchers frame the goal as extending therapists’ reach, with a long term clinical study still to come. Source: MIT Technology Review

    7. FDA finalizes guidance on software tied to prescription drugs Published in the Federal Register on 21 October, the guidance explains that software outputs distributed by or for a drug sponsor can be treated as prescription drug labeling, with consequences for prescribing information and FDA review. It matters because any digital companion built around a drug now has a clearer, and more demanding, set of labeling expectations. Source: Federal Register

    8. Provider groups tell FDA that AI makers, not doctors, should carry the risk Healthcare Dive reported on 22 October that the AHA, AMA and ATA, responding to FDA’s generative AI discussion paper, argued that developers must monitor and answer for the performance of generative AI devices. It matters because the director of FDA’s Digital Health Center of Excellence said draft guidance is planned in the coming months, so this liability debate will shape the rules you build against. Source: Healthcare Dive

    Gary’s take The MHRA decision is the item I would act on first, because regulatory certainty is worth more to a small MedTech company than almost any single product news, and it means a CE mark can remain the backbone of a British entry plan. Alongside it, the NeuroXT clearance shows how quickly AI software that supports a neurology decision can become a cleared product once the intended use is kept honest and narrow, here as supplementary information for the clinician and not a diagnosis on its own, and I expect the generative AI guidance that is coming in the next months to reward exactly that discipline.

    What was the most useful MedTech development you saw this week, and which area should I cover more closely next time? You are also welcome to write to me directly.


    Sources note: items 1, 2 and 4 came from a LinkedIn scan of the week and were checked against their original sources.

    Website: synergenmedtech.com | LinkedIn: linkedin.com/company/100981535 | YouTube: youtube.com/@synergenmedtech

  • Why Healthcare Business Development Requires More Than a Great Product

    Why Healthcare Business Development Requires More Than a Great Product

    I have spent about 30 years turning ideas into businesses, most of them in medical technology, and I have worked on more than 20 medical products along the way, from software to cardiovascular and neurological devices. If I had to sum up what those years taught me about healthcare business development in one sentence, it would be a line I wrote on my own website: I have seen excellent technologies fail commercially, and relatively ordinary products become successful businesses, and the difference often has very little to do with the technology itself.

    That is a hard thing to say to an inventor who has given years of their life to a device, and I say it gently. But I think it is the most useful place to begin this series, because almost every other lesson about business development and marketing in our industry follows from it.

    A great product is where the work starts

    Founders usually come to business development after years of engineering, clinical work and regulatory effort, and it is natural for them to believe that the product will speak for itself once it is ready. In most industries a better product does have a good chance of winning. In healthcare it is only the entry ticket. A clinician may love your device and still be unable to use it, because the hospital has no budget line for it, because nobody will pay for the procedure, or because it does not fit into a working day that is already full.

    The people who decide whether a medical device succeeds are many, and they rarely sit in the same room. There is the physician or therapist who uses it, the administrator who controls the budget, the payer who decides whether the treatment is covered, the regulator in each country, and in most international markets a distributor who decides whether your product deserves attention next to everything else they carry. Healthcare business development is the work of understanding each of those people, what they need to hear and what they are risking by saying yes, and then building a path that makes sense for all of them at once.

    What I learned from selling without a code

    My clearest lesson in this came early in my career, when I established and led the US subsidiary of a medical device company I worked for. We built it into a solid business within three years, despite the fact that there was no CPT code for the procedure, which meant that clinicians had no simple way to be paid for using the device. These products had over 50 peer reviewed publications but no direct code. The AMA was against us, the Societies were against us, the leading physicians were against us, because we would cut their income by up to 80%. No one would support us, but we went forward and in the end succeeded and today, these technologies have overtaken the traditional ones.

    People sometimes assume there must have been a clever trick behind that. There was no trick. When the payment system has not caught up with your technology, you are selling clinical value and economics directly to the people who live with the problem every day, one site at a time, and every satisfied clinician becomes the reason the next one agrees to listen. Because of having no code, we could not sell to the traditional market, and had to find alternative markets. Not easy, but we did it and we reached sales in the millions of dollars.

    What that experience taught me was humility about the product. The device was good, but it was the work around it that made the business: understanding how each clinic was run, what it cost them to adopt something new, and which arguments mattered to the person who signed the order. Since then, the first questions I ask about any medical technology are about the world around the device, who will pay for it and what evidence that payer will need to see, because the answers usually shape the clinical study, the price and often the product itself.

    Healthcare business development is built on relationships

    The second thing a great product cannot do on its own is build trust. In my experience, healthcare is one of the most relationship driven industries in the world, because the people buying are responsible for patients, and they are understandably careful about who they let into that responsibility. A hospital department will often prefer a supplier it has known for years over a better product from a company it has never met, and a distributor will think very carefully before putting its own reputation behind a newcomer.

    That means business development in healthcare is slow in a way that can frustrate founders who come from faster industries. Relationships with distributors, hospitals and regulators take years to build, and they have to be started well before you need an order. The companies I have seen do this well begin talking to the people who will eventually buy and sell their product long before the design is frozen, and they keep showing up in person, even when there is nothing new to announce.

    Development and entrepreneurship together

    Some years ago I coined a word for the combination of skills this requires: Developeneurship, a fusion of development and entrepreneurship. Entrepreneurship is the moment of seeing an opportunity, and development is everything that has to happen afterwards for that opportunity to become real. Can you develop the product to the point where it is safe and manufacturable? Can you find customers in markets you have never worked in? And can you survive long enough to build a sustainable business while all of that is happening?

    Very few founding teams are strong at both, and that is no criticism of anyone. Most medical technology companies are started by brilliant engineers and clinicians, and what they usually lack is someone who has already taken a product through clearance and into distribution in several countries. Recognizing that gap early is one of the most valuable things a founder can do, because it changes who you hire, who you ask for advice and how you plan your first years.

    What a business development plan should answer

    In practice, I encourage founders to treat business development as a discipline from the very beginning rather than an activity that starts after launch. A good plan answers a small number of honest questions. Who will pay for this, in each market where you want to sell? What evidence will they need to see? Which markets come first, and why those? Who will sell the product there, and what will they need from you to do it with confidence? And who in your company has the time and experience to build those relationships over several years?

    None of these questions has a quick answer, and most young companies cannot answer all of them on the day they start. That is perfectly normal. What matters is that they are asked early, while there is still time to shape the product, the study and the budget around the answers. Has it always worked for me? Absolutely not. I have had successes and failures, and more unexpected challenges than I care to remember, but almost every failure I have seen, my own included, began with a belief that the product would be enough.

    Over the next articles in this series I want to follow that path step by step, from deciding where to start internationally, through choosing markets, partners and commercial models, to building the relationships and the launch that turn a good device into a business.

    At Synergen MedTech Consultants, this is the work I do every day with medical technology companies. If your product is ready but the business around it is not yet clear, I would be glad to talk. Write to me at gary@synergenmedtech.com and tell me about your commercialization or international business development challenges. In the next article, I look at where international business development should actually start.

    All names of people and partners have been removed for privacy reasons.

    Website: synergenmedtech.com | LinkedIn: linkedin.com/company/100981535 | YouTube: youtube.com/@synergenmedtech